A phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2012
At a glance
- Drugs Lapatinib (Primary) ; Topotecan
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Mar 2012 Actual end date changed from Mar 2009 to Feb 2012 as reported by ClinicalTrials.gov.
- 28 Oct 2011 Actual end date (March 2009) added as reported by ClinicalTrials.gov.